Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Double-Blinded, Placebo-Controlled 16-Week Study (With a 52-Week Open-Label Extension) to Assess the Safety and Efficacy of Etrasimod in Subjects With Moderate-to-Severe Atopic Dermatitis

NCT04162769 is registered in ClinicalTrials.gov with Arena Pharmaceuticals as lead sponsor.

NCT NCT04162769
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04162769 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Double-Blinded, Placebo-Controlled 16-Week Study (With a 52-Week Open-Label Extension) to Assess the Safety and Efficacy of Etrasimod in Subjects With Moderate-to-Severe Atopic Dermatitis
Lead sponsor
Arena Pharmaceuticals
Phase
Phase 2
Overall status
Completed
Start date
October 4, 2019
Completion date
October 11, 2021
Enrollment
140 (actual)
Sites
38

Conditions

As the registry lists them; a condition with its own page is linked.

atopic dermatitis